Mount Sinai and AllerGenis, LLC Announce Partnership to Bring Novel, Precision Diagnostics to Food Allergy Patients
New Diagnostic Technology Will Provide Information to Both Patients and Clinicians More than 30 million people in the United States and Europe have food allergies, according to the National Institute of Allergy and Infectious Diseases, National Institutes of Health. AllerGenis’ food allergy …
RxHealth™ Raises $1.8 Million Seed Round, Launches Bulk Prescription™ to Population Health Programs
Digital medicine platform Rx.Health, a Mount Sinai Health System spinoff and provider of RxUniverse™, recently announced that it has raised $1.8 million in seed funding. The funding will be used to diversify Rx.Health’s client base and support its first-to-market Bulk Prescription™ digital …
Mount Sinai and Novotalk sign a joint venture agreement to bring innovative speech and language therapeutic technologies to patients
On-demand (virtual) health solutions enable the patient to undergo a therapeutic process with a computer acting as a virtual clinician • The licensed clinicians supervise the process, leveraging mass data collection for clinical insights not otherwise available in a regular clinical setting …
Erik Lium, PhD, Promoted to Executive Vice President of Mount Sinai Innovation Partners
The Mount Sinai Health System has announced Erik Lium, PhD, has been promoted to Executive Vice President of Mount Sinai Innovation Partners (MSIP). His new, expanded role will include broad responsibilities for innovation, commercialization, and entrepreneurship across the Mount Sinai Health System …
Mount Sinai and RenalytixAI Launch Groundbreaking Artificial Intelligence Solution For Improved Kidney Disease Management and Patient Care
Artificial Intelligence (AI) will be deployed against Mount Sinai’s massive patient data warehouse biorepository and to innovate more accurate disease detection and management for introduction in 2019 Kidney disease is a public health crisis affecting an estimated 12% or 120 million of …
Mount Sinai Launches the i3 Asset Accelerator to Advance the Development of Life-Saving Discoveries
The Icahn School of Medicine at Mount Sinai and Mount Sinai Innovation Partners today announced the launch of the i3 Asset Accelerator, a new fund that fast-tracks select research discoveries to reach patients sooner, and has selected its first two projects to …
Ground-breaking Collaboration pursues the early detection of Endometrial and Ovarian Cancers
Mirage News: New York City-based Icahn School of Medicine at Mount Sinai and Adelaide, South Australia-based Numedico Technologies, have signed a Collaboration Development Agreement (CDA). The international collaboration team will design, develop and commercialise a device for the screening and early detection of …
ShangPharma Innovation And Icahn School Of Medicine At Mount Sinai Forge Translational Research Collaboration
Medical Health News ShangPharma Innovation Inc., a global venture capital firm focused on biomedical R&D therapeutics and technologies, and the Icahn School of Medicine at Mount Sinai has entered into a multi-year strategic collaboration to accelerate the development of novel early-stage therapeutics. …
Compugen to Enter Research Collaboration with Mount Sinai on Novel Myeloid Immuno-Oncology Targets
Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the initiation of a multi-year cancer immunotherapy research collaboration with Mount Sinai, under the direction of Miriam Merad, MD, PhD, Director of the …
InDevR Licenses Mount Sinai Influenza Antibodies for VaxArray® Neuraminidase Potency Assay
InDevR, a Boulder-based progressive analytical technology and life science instrumentation company today announced that it has entered into an exclusive, world-wide license agreement for monoclonal antibodies developed by scientists at the Icahn School of Medicine at Mount Sinai. The license agreement with Mount …